174 related articles for article (PubMed ID: 18272318)
1. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Kandutsch S; Klinger M; Hacker S; Wrba F; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2008 Nov; 34(11):1231-6. PubMed ID: 18272318
[TBL] [Abstract][Full Text] [Related]
2. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Aloia T; Sebagh M; Plasse M; Karam V; Lévi F; Giacchetti S; Azoulay D; Bismuth H; Castaing D; Adam R
J Clin Oncol; 2006 Nov; 24(31):4983-90. PubMed ID: 17075116
[TBL] [Abstract][Full Text] [Related]
3. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
Nakano H; Oussoultzoglou E; Rosso E; Casnedi S; Chenard-Neu MP; Dufour P; Bachellier P; Jaeck D
Ann Surg; 2008 Jan; 247(1):118-24. PubMed ID: 18156931
[TBL] [Abstract][Full Text] [Related]
4. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
5. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.
Coskun U; Buyukberber S; Yaman E; Uner A; Er O; Ozkan M; Dikilitas M; Oguz M; Yildiz R; B DY; Kaya AO; Benekli M
Neoplasma; 2008; 55(1):65-70. PubMed ID: 18190244
[TBL] [Abstract][Full Text] [Related]
6. [A case of liver failure associated with liver damage due to mFOLFOX 6 after resection for multiple liver metastases from colorectal cancer].
Ishizaki T; Abe T; Koyanagi Y; Katsumata K; Wada T; Tsuchida A; Aoki T
Gan To Kagaku Ryoho; 2007 Jun; 34(6):945-8. PubMed ID: 17565263
[TBL] [Abstract][Full Text] [Related]
7. Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
Popov IP; Milicevic M; Kecmanovic D; Tomasevic Z; Radosevic-Jelic Lj; Borojevic N; Micev MT; Kezic I
J Exp Clin Cancer Res; 2006 Sep; 25(3):313-9. PubMed ID: 17167970
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
Seki H; Ozaki T; Shiina M
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
[TBL] [Abstract][Full Text] [Related]
9. [Predictive factors for histopathological liver injury in the patients who received preoperative systemic chemotherapy for colorectal liver metastases].
Kudo D; Tsutsumi S; Akasaka H; Jin H; Ohashi T; Muroya T; Hasebe T; Sakamoto Y; Ishido K; Koyama M; Toyoki Y; Murata A; Narumi S; Kijima H; Hakamada K
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2025-7. PubMed ID: 20037312
[TBL] [Abstract][Full Text] [Related]
10. Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastases.
Pathak S; Tang JM; Terlizzo M; Poston GJ; Malik HZ
Eur J Surg Oncol; 2010 Jan; 36(1):52-7. PubMed ID: 19879103
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
12. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases.
Neumann UP; Thelen A; Röcken C; Seehofer D; Bahra M; Riess H; Jonas S; Schmeding M; Pratschke J; Bova R; Neuhaus P
Surgery; 2009 Jul; 146(1):52-9. PubMed ID: 19541010
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases.
Hubert C; Fervaille C; Sempoux C; Horsmans Y; Humblet Y; Machiels JP; Zech F; Ceratti A; Gigot JF
Surgery; 2010 Feb; 147(2):185-94. PubMed ID: 20109620
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful?
Abdalla EK; Vauthey JN
Dig Surg; 2008; 25(6):421-9. PubMed ID: 19212114
[TBL] [Abstract][Full Text] [Related]
16. [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].
Kuboki Y; Ichimura T; Ogura M; Matsuda M; Suenaga M; Shinozaki E; Matsuzaka S; Chin K; Mizunuma N; Hatake K
Gan To Kagaku Ryoho; 2008 May; 35(5):781-5. PubMed ID: 18487913
[TBL] [Abstract][Full Text] [Related]
17. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Khan AZ; Morris-Stiff G; Makuuchi M
J Hepatobiliary Pancreat Surg; 2009; 16(2):137-44. PubMed ID: 19093069
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy.
Hewes JC; Riddy D; Morris RW; Woodrooffe AJ; Davidson BR; Fuller B
J Hepatol; 2006 Aug; 45(2):263-70. PubMed ID: 16635536
[TBL] [Abstract][Full Text] [Related]
19. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Tamandl D; Gruenberger B; Herberger B; Kaczirek K; Gruenberger T
J Surg Oncol; 2009 Oct; 100(5):364-71. PubMed ID: 19235181
[TBL] [Abstract][Full Text] [Related]
20. Preoperative systemic 5-fluorouracil does not increase the risk of liver resection.
Parc Y; Dugué L; Farges O; Hiramatsu K; Sauvanet A; Belghiti J
Hepatogastroenterology; 2000; 47(36):1703-5. PubMed ID: 11149036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
